Assembly Biosciences, Inc (ASMB)
PHARMACEUTICAL PREPARATIONS
Assembly Biosciences, Inc (ASMB) is listed on Nasdaq, where it has traded since December 17, 2010.
- Listed On
- Nasdaq
- Listed Since
- December 17, 2010
- Employees
- 73
- Market Cap
- $419M
About Assembly Biosciences, Inc
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 90 institutions reported holding ASMB, with 18.7 million shares worth $514.8 million in aggregate. The largest reported holder was Gilead Sciences, with 5.0 million shares worth $136.8 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Gilead Sciences | 4,977,089 | $137M | Added 10.47% |
| Farallon Capital Management | 1,604,590 | $44M | Added 30.71% |
| Paradigm Biocapital Advisors | 1,553,748 | $43M | Added 133.56% |
| Commodore Capital | 1,415,000 | $39M | Added 41.5% |
| RA Capital Management | 1,020,410 | $28M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ASMB?
Assembly Biosciences, Inc (ASMB) is listed on Nasdaq, where it has traded since December 17, 2010.
Who are the largest institutional holders of ASMB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ASMB were Gilead Sciences, Farallon Capital Management and Paradigm Biocapital Advisors.
How many institutions own ASMB?
90 institutions reported a position in ASMB for the quarter ended June 30, 2026, worth $514.8 million in total.
Did institutions buy or sell ASMB last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ASMB.
Every reported institutional holder, plus insider and congressional trades in ASMB, on SentiSense.